vs
Side-by-side financial comparison of InMed Pharmaceuticals Inc. (INM) and Nakamoto Inc. (NAKA). Click either name above to swap in a different company.
InMed Pharmaceuticals Inc. is the larger business by last-quarter revenue ($820.2K vs $444.9K, roughly 1.8× Nakamoto Inc.). Nakamoto Inc. runs the higher net margin — 8374.2% vs -247.3%, a 8621.5% gap on every dollar of revenue. On growth, InMed Pharmaceuticals Inc. posted the faster year-over-year revenue change (-26.2% vs -26.3%). Over the past eight quarters, InMed Pharmaceuticals Inc.'s revenue compounded faster (-16.4% CAGR vs -26.7%).
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
INM vs NAKA — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $820.2K | $444.9K |
| Net Profit | $-2.0M | $37.3M |
| Gross Margin | 22.5% | — |
| Operating Margin | -247.3% | -41198.2% |
| Net Margin | -247.3% | 8374.2% |
| Revenue YoY | -26.2% | -26.3% |
| Net Profit YoY | 21.2% | 3820.2% |
| EPS (diluted) | $-0.51 | $0.68 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $820.2K | $444.9K | ||
| Q3 25 | $1.1M | $388.2K | ||
| Q2 25 | $1.3M | $408.5K | ||
| Q1 25 | $1.3M | $579.7K | ||
| Q4 24 | $1.1M | $603.9K | ||
| Q3 24 | $1.3M | $647.9K | ||
| Q2 24 | $1.3M | $639.1K | ||
| Q1 24 | $1.2M | $829.0K |
| Q4 25 | $-2.0M | $37.3M | ||
| Q3 25 | $-1.7M | $-86.0M | ||
| Q2 25 | $-1.8M | $-2.4M | ||
| Q1 25 | $-2.1M | $-1.0M | ||
| Q4 24 | $-2.6M | $-1.0M | ||
| Q3 24 | $-1.7M | $-1.0M | ||
| Q2 24 | $-1.9M | $-1.3M | ||
| Q1 24 | $-1.7M | $-282.3K |
| Q4 25 | 22.5% | — | ||
| Q3 25 | 36.0% | — | ||
| Q2 25 | 44.2% | — | ||
| Q1 25 | 13.9% | — | ||
| Q4 24 | 41.5% | — | ||
| Q3 24 | 39.0% | — | ||
| Q2 24 | 36.3% | — | ||
| Q1 24 | 24.7% | — |
| Q4 25 | -247.3% | -41198.2% | ||
| Q3 25 | -154.2% | -2680.4% | ||
| Q2 25 | -137.1% | -585.4% | ||
| Q1 25 | -168.1% | -179.7% | ||
| Q4 24 | -231.6% | -169.3% | ||
| Q3 24 | -132.7% | -162.0% | ||
| Q2 24 | -150.5% | -162.3% | ||
| Q1 24 | -146.9% | -28.6% |
| Q4 25 | -247.3% | 8374.2% | ||
| Q3 25 | -154.2% | -22162.2% | ||
| Q2 25 | -137.1% | -590.9% | ||
| Q1 25 | -168.1% | -179.1% | ||
| Q4 24 | -231.6% | -165.8% | ||
| Q3 24 | -132.7% | -156.5% | ||
| Q2 24 | -151.0% | -206.5% | ||
| Q1 24 | -146.9% | -34.1% |
| Q4 25 | $-0.51 | $0.68 | ||
| Q3 25 | $-0.44 | $-0.42 | ||
| Q2 25 | $-0.07 | $-0.35 | ||
| Q1 25 | $-1.94 | $-0.17 | ||
| Q4 24 | $-3.64 | $-0.18 | ||
| Q3 24 | $-2.71 | $-0.17 | ||
| Q2 24 | $2.39 | $-0.26 | ||
| Q1 24 | $-3.58 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.0M | $22.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $9.6M | $514.3M |
| Total Assets | $11.2M | $730.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $7.0M | $22.6M | ||
| Q3 25 | $9.4M | $24.2M | ||
| Q2 25 | $11.1M | $6.0M | ||
| Q1 25 | $4.7M | $1.1M | ||
| Q4 24 | $3.5M | $2.3M | ||
| Q3 24 | $5.6M | $3.6M | ||
| Q2 24 | $6.6M | $4.7M | ||
| Q1 24 | — | $287.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $64.4K | ||
| Q4 24 | — | $148.8K | ||
| Q3 24 | — | $205.6K | ||
| Q2 24 | — | $254.7K | ||
| Q1 24 | — | $710.0K |
| Q4 25 | $9.6M | $514.3M | ||
| Q3 25 | $11.6M | $477.6M | ||
| Q2 25 | $13.4M | $9.0M | ||
| Q1 25 | $7.0M | $1.5M | ||
| Q4 24 | $6.2M | $2.6M | ||
| Q3 24 | $8.4M | $3.5M | ||
| Q2 24 | $9.2M | $4.4M | ||
| Q1 24 | $11.1M | $-383.1K |
| Q4 25 | $11.2M | $730.6M | ||
| Q3 25 | $13.4M | $692.4M | ||
| Q2 25 | $15.6M | $9.9M | ||
| Q1 25 | $9.3M | $2.6M | ||
| Q4 24 | $8.5M | $3.7M | ||
| Q3 24 | $10.5M | $4.3M | ||
| Q2 24 | $11.8M | $5.5M | ||
| Q1 24 | — | $799.3K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 0.04× | ||
| Q4 24 | — | 0.06× | ||
| Q3 24 | — | 0.06× | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.4M | $-23.5M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | -0.63× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.4M | $-23.5M | ||
| Q3 25 | $-1.6M | $-13.2M | ||
| Q2 25 | $-1.8M | $-1.9M | ||
| Q1 25 | $-1.7M | $-865.1K | ||
| Q4 24 | $-2.5M | $-3.1M | ||
| Q3 24 | $-1.8M | $-1.0M | ||
| Q2 24 | $-1.0M | $-913.5K | ||
| Q1 24 | $-1.9M | $-213.4K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $-3.1M | ||
| Q3 24 | — | $-1.0M | ||
| Q2 24 | — | — | ||
| Q1 24 | $-1.9M | $-224.6K |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -511.2% | ||
| Q3 24 | — | -161.7% | ||
| Q2 24 | — | — | ||
| Q1 24 | -165.0% | -27.1% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.2% | ||
| Q3 24 | — | 0.3% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | 0.0% | 1.3% |
| Q4 25 | — | -0.63× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
